Amgen declares fourth-quarter dividend
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Tri-county biotech upstarts struggle to maintain stock prices
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Sienna Biopharmaceuticals filing for Chapter 11 bankruptcy
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Coastal Dispensary opens, plans manufacturing hub
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen trades cash for cash flow with Otezla deal
Amgen’s $13.4 billion acquisition of lucrative psoriasis therapy Otezla secures nearly a decade of revenue growth for the biotech giant to bridge the gap between its waning legacy products and potential new contenders. The relatively small deal could nonetheless change the landscape of the biotech industry, allowing regulators to approve a $74 billion takeover bid Read More →
Judge overturns verdict upholding Repatha patents
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen’s stock climbs after announcing Otezla acquisition
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
